CoChat

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial

Open access
Grosso, Federica, Steele, Nicola, Novello, Silvia, Nowak, Anna K., Popat, Sanjay, Greillier, Laurent, John, Thomas, Leighl, Natasha B., Reck, Martin, Taylor, Paul, Planchard, David, Sørensen, Jens Benn, Socinski, Mark A., von Wangenheim, Ute, Loembé, Arsène Bienvenu, Barrueco, José, Morsli, Nassim, Scagliotti, Giorgio · 2017 · Journal of Clinical Oncology
Cited by 143

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Purpose: LUME-Meso is a phase II/III randomized, double-blind trial designed to assess efficacy and safety of nintedanib plus chemotherapy as first-line treatment of malignant pleural mesothelioma (MPM). Phase II results are reported here. Patients and Methods: Chemotherapy-naïve patients with unresectable, nonsarcomatoid MPM (Eastern Cooperative Oncology Group performance status 0 to 1), stratified by histology (epithelioid or biphasic), were randomly assigned in a 1:1 ratio to up to six cycles of pemetrexed and cisplatin plus nintedanib (200 mg twice daily) or placebo followed by nintedanib plus placebo monotherapy until progression. The primary end point was progression-free survival (PFS). Results: Eighty-seven patients were randomly assigned. The median number of pemetrexed and cisplatin cycles was six; the median treatment duration for nintedanib was 7.8 months and 5.3 months for placebo. Primary PFS favored nintedanib (hazard ratio [HR], 0.56; 95% CI, 0.34 to 0.91; P = .017), which was confirmed in updated PFS analyses (HR, 0.54; 95% CI, 0.33 to 0.87; P = .010). A trend toward improved overall survival also favored nintedanib (HR, 0.77; 95% CI, 0.46 to 1.29; P = .319). Benefit was evident in epithelioid histology, with a median overall survival gain of 5.4 months (HR, 0.70; 95% CI, 0.40 to 1.21; P = .197; median [nintedanib v placebo], 20.6 months v 15.2 months) and median PFS gain of 4.0 months (HR, 0.49; 95% CI, 0.30 to 0.82; P = .006; median [nintedanib v placebo], 9.7 v 5.7 months). Neutropenia was the most frequent grade ≥ 3 adverse event (AE; nintedanib 43.2% v placebo 12.2%); rates of febrile neutropenia were low (4.5% in nintedanib group v 0% in placebo group). AEs leading to discontinuation were reported in 6.8% of those receiving nintedanib versus 17.1% of those in the placebo group. Conclusion: Addition of nintedanib to pemetrexed plus cisplatin resulted in PFS improvement. AEs were manageable. The clinical benefit was evident in patients with epithelioid histology. The confirmatory phase III part of the study is ongoing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2017.72.9012

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 29

  1. 10.1371/journal.pone.0145039 · DOI · Paper page
  2. Robinson BM, 2012, Ann Cardiothorac Surg, 1, 491
  3. 10.1016/j.jtho.2016.04.028 · DOI · Paper page
  4. 10.1183/09059180.00007014 · DOI · Paper page
  5. 10.1093/annonc/mdv199 · DOI · Paper page
  6. 10.1097/JTO.0b013e318229586e · DOI · Paper page
  7. 10.1097/JTO.0b013e31825f22ee · DOI
  8. 10.1097/JTO.0b013e3181ec18db · DOI · Paper page
  9. 10.1097/JTO.0b013e318248242c · DOI
  10. 10.1080/14737140.2016.1244008 · DOI
  11. 10.2147/OTT.S78805 · DOI
  12. 10.1002/path.824 · DOI · Paper page
  13. 10.1056/NEJMra050152 · DOI · Paper page
  14. 10.1002/ijc.10996 · DOI
  15. 10.1002/dc.20767 · doi:10.1002/dc.20767
  16. 10.1158/1535-7163.MCT-07-0052 · DOI
  17. 10.18632/oncotarget.126 · DOI
  18. 10.1007/s10585-004-3150-2 · doi:10.1007/s10585-004-3150-2
  19. 10.1093/annonc/mdr596 · DOI
  20. 10.1093/annonc/mdv286 · DOI
  21. 10.1158/1078-0432.CCR-09-2944 · DOI
  22. 10.1038/bjc.2011.440 · DOI
  23. 10.1093/annonc/mdh059 · DOI · Paper page
  24. 10.1016/j.anndiagpath.2014.02.005 · DOI
  25. Laszlo V, Ozsar J, Klikovits T, et al: Preclinical investigation of the therapeutic potential of nintedanib in malignant pleural mesothelioma. 13th International Conference of the International Mesothelioma Interest Group, Birmingham, United Kingdom, May 1-4, 2016 (abstr)
  26. Lakatos D, Hegedus B, Laszlo V, et al: Nintedanib-induced motility response in mesothelioma cells. Poster presented at the Semmelweis Symposium: Molecular Oncology: from bench to bedside. Budapest, Hungary, November 5-6, 2015
  27. 10.1016/S1470-2045(15)00366-6 · DOI · Paper page
  28. 10.2217/lmt.15.33 · DOI
  29. 10.1634/theoncologist.2016-0121 · DOI

Cited by

Metadata

Authors
Grosso, F., Steele, N., Novello, S., Nowak, A. K., Popat, S., Greillier, L., John, T., Leighl, N. B., Reck, M., Taylor, P., Planchard, D., Sørensen, J. B., Socinski, M. A., von Wangenheim, U., Loembé, A. B., Barrueco, J., Morsli, N., & Scagliotti, G.
Venue
Journal of Clinical Oncology
Published
2017-11-01
Volume
35
Issue
31
Pages
3591-3600
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2755663477
Cited by
143
References
4
FWCI
15.59
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.